A clinical trial of the anti-malaria drug hydroxychloroquine on Covid19 patients has been suspended by the World Health Organisation amid health risk.
The anti-malaria drug had previously been promoted by President Donald Trump for coronavirus treatment and he also acknowledged taking it for a period of two weeks as a prophylactic.
But the World Health Organization (WHO) said it was concerned after a study from The Lancet published on Friday revealed higher mortality rates among COVID-19 patients who took the drug.
Recall that Travis news earlier reported that investigations from US medical experts suggest that hydroxychloroquine could be linked to many US deaths.
Therefore, researchers said they’re suspending the use of hydroxychloroquine in the WHO’s Solidarity Trial, which is to evaluate the safety and efficacy of four drugs and drug combinations against the virus.